August 14, 2007 04:04 ET

VIVALIS announces its 1st semester 2007 revenues

NANTES, FRANCE--(Marketwire - August 14, 2007) -

VIVALIS (Euronext Paris : VLS), a biopharmaceutical company specialised in development and marketing of technologies dedicated to the production of vaccines and production of antiviral diseases products, announces its revenues for the first quarter 2007 and the 1st semester 2007, closing June 30th 2007.

(VAT, in thousands of Euros, French Accounting Principles)

|  Fiscal Year|  2007|  2006 |
|  1st quarter|   470|    530|
|  2nd Quarter|   470|    478|
|  Total      |   940|  1 008|
(*) Revenues include fees for services and licensing incomes

Next calendar:

August 30th, after Euronext closing: First half 2007 results


Vivalis (Euronext: VLS) is a biopharmaceutical company specialised in vaccines and in viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants commercial licences to its proprietary EBx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.

- Recombinant therapeutic protein and monoclonal antibody expression systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary EBx® embryonic stem cell lines to manufacture recombinant therapeutic proteins.

- The build-up of a proprietary portfolio of vaccines and anti-viral molecules.

Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n degrees2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

B Compartment of Eurolist Paris - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

Investors Contact:


Franck Grimaud, C.E.O.

Tel. + 33 2 28 07 37 10


This information is provided by CompanynewsGroup

Contact Information